Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
Authors:
- Luigi GennariLuigi Gennari
- Daniela MerlottiDMDaniela Merlotti
- Ranuccio NutiRNRanuccio Nuti
Open Access
- 1 January 2010
- journal article
- review article
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. 5, 19-29
Abstract
Peer reviewed article authored by (Luigi Gennari, Daniela Merlotti, Ranuccio Nuti). Read article or submit your manuscript for publishing.Keywords
This publication has 63 references indexed in Scilit:
- Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since MenopauseJAMA, 2007
- Selective Estrogen Receptor Modulators for Postmenopausal OsteoporosisDrugs & Aging, 2007
- Effect of Lasofoxifene on the Pharmacokinetics of Digoxin in Healthy Postmenopausal WomenThe Journal of Clinical Pharmacology, 2005
- LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model.2001
- Therapeutic potential of oestrogen receptor ligands in development for osteoporosisExpert Opinion on Emerging Drugs, 2001
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999
- Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.1996
- Bone density at various sites for prediction of hip fracturesThe Lancet, 1993
- Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.1990
- Effects of anti-estrogens on bone in castrated and intact female ratsBreast Cancer Research and Treatment, 1987